Key Points

  • HIMS) has collapsed 75.50% from its May 2025 peak of $64.65, currently trading in deep value territory.
  • A February 2026 lawsuit from NVO) regarding unapproved semaglutide marketing triggered the rout, yet core telehealth segments remain robust.
  • Wall Street maintain an average price target of $39.32, implying a 148% upside as the stock reaches a technical RSI floor of 16.87.

The meteoric rise of HIMS has met a brutal correction, leaving investors to weigh a staggering 75% drawdown against the fundamental strength of a digital health disruptor. After touching an all-time high of $64.65 in May 2025, the stock has been in a sustained free fall, exacerbated by a high-stakes legal offensive from pharmaceutical giant NVO. The February 2026 lawsuit, which alleges the unlawful marketing of unapproved semaglutide versions, has stripped billions from the company’s market capitalization, but a growing chorus of analysts suggests the sell-off has decoupled from reality.

The GLP-1 Legal Crossfire and Market Reaction

The primary catalyst for the recent volatility is the intensifying friction between the compounding pharmacy model and Big Pharma. Novo Nordisk’s litigation directly challenges the high-margin weight loss segment that fueled much of Hims & Hers’ growth over the past year. However, institutional desks are closely monitoring the [insider trading tracker](/insider-trading) to see if management's conviction matches their public statements. While the legal overhang is undeniable, the panic selling has pushed the Relative Strength Index (RSI) to a subterranean 16.87. In technical terms, this is not just oversold; it is a historical outlier that typically precedes a sharp mean-reversion move.

Beyond the headlines of the GLP-1 battle, the company’s infrastructure continues to scale. Hims & Hers is expected to report record quarterly revenue of $619 million on February 23. This figure represents a significant year-over-year jump, suggesting that the underlying demand for telehealth services—ranging from hair thinning treatments to sexual health supplements—remains insulated from the regulatory noise surrounding weight loss injectables. For those looking for top stock picks for beginners, the current entry point offers a rare venture-style upside in a company that is already generating substantial cash flow.

What It Means for Investors

For the retail investor, the divergence between price and performance creates a complex risk-reward profile. While the NVO lawsuit introduces a layer of binary risk, the analyst community remains remarkably steadfast. The consensus 12-month price target of $39.32 indicates that professionals are looking past the immediate litigation cycle toward the long-term utility of the Hims platform. Sophisticated traders are increasingly utilizing [AI trading tools](/ai-traders) to parse the sentiment shifts, as the stock has become a favorite for high-frequency volatility plays.

Market participants are also keeping a close eye on Washington. In an era where healthcare policy is a central campaign pillar, many are asking what stocks are politicians buying to gauge the potential for regulatory shifts that could favor telehealth providers over traditional pharmaceutical monopolies. If Hims & Hers can successfully navigate the compounding pharmacy regulations, the current price will likely be viewed as a generational buying opportunity. The company’s diversified portfolio in mental health and dermatology provides a safety net that the market is currently valuing at near-zero.

The Bottom Line

The current capitulation in HIMS shares feels more like a liquidity event than a fundamental collapse. With a massive revenue beat likely on the horizon and a technical setup that screams exhaustion from sellers, the stage is set for a potential bullish reversal. While the Novo Nordisk litigation will take time to wind through the courts, the sheer velocity of the 75% drop has likely priced in the worst-case scenario. For investors with a high risk tolerance, the 150% projected upside isn't just a hopeful forecast—it is a reflection of a business that is growing much faster than its stock price would suggest.